A Ph. IIb TYK2 inhibitor from Nimbus (just bought by Takeda) that may be more efficacious than deucravacitinib, the first and only approved CGRP receptor antagonist nasal spray for the treatment of acute migraines from BMS/Pfizer, a pomalidomide-derived Ph. I/Ib oral, IKZF2-selective molecular glue degrader for the treatment of advanced solid tumors from Novartis are just some of the examples for this month's MOTM.
Learn more about the molecules by navigating to the full reviews on the right (when released) which cover: why the molecules matter, how they were discovered, the key steps behind optimization, how they work, why the targets were chosen, any interesting toxicology and clinical data, and more.
In the meantime, as we release the full reviews throughout this month, you can find the article links that inspired us to write up these stories below:
- TAK-279 - a Ph. Ilb oral, once-daily allosteric TYK2 inhibitor from Nimbus/Takeda
- zavegepant - the first and only approved CGRP receptor antagonist nasal spray from BMS/Pfizer
- revumenib - a Ph. I/II oral menin-KMT2A inhibitor from Vitae/Syndax
- zunsemetinib - a Ph. IIa oral MK2 inhibitor from Confluence/Aclaris Therapeutics
- JNJ-1802 - a Ph. I oral first-in-class DENV (NS3-NS4B) inhibitor from Janssen
- nirogacestat - a Ph. III oral gamma secretase inhibitor from Pfizer/SpringWorks
- linvencorvir - a Ph. II oral allosteric HBV modulator from Roche Shanghai
- KW-6356 - a Ph. II oral A2A receptor antagonist/inverse agonist from Kyowa Kirin
- DKY709 - a Ph. I/Ib oral IKZF2-selective molecular glue degrader from Novartis
- ACT-777991 - a Ph. I oral reversible CXCR3 antagonist from Idorsia Pharmaceuticals
Sign up for our free weekly newsletter here to get more content like this straight to your inbox. Not a member? Get a free trial to check out substructure search and more features.